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C.H. Ladel1, A. Gimona2, J.L. Ellsworth3, A. Bendele4, E. vom Baur2.
1Merck Serono Research – RBM, Colleretto Giacosa, ITALY , 2Merck
Serono S.A., Geneva, SWITZERLAND, 3ZymoGenetics inc., Seattle,
WA. USA, 4Bolder BioPATH, Inc., Bolder, CO, USA
Purpose: To determine the effects of intra-articular administration of
recombinant human ﬁbroblast growth factor 18 (rhFGF18, AS902330) in
a pilot study of a dog meniscectomy model for established osteoarthritis.
Methods: A unilateral partial medial meniscectomy was performed on
the left knee of female beagle dogs 1 month prior to intra-articular
administration of 3, 10 or 30mg/joint of AS902330 or saline (control)
as a single dose, or as a once-weekly or 3-times-weekly (tiw; 3, 10
or 30mg divided between 3 doses) dose for 3 weeks. At treatment end
(day 22), the dogs were anaesthetized before euthanasia. Left knee joints
were collected for gross, microscopic and histopathological evaluation. A
scoring system was used for histopathology of the cartilage and for gross
pathology; reading was conducted in a blinded manner. Blood and serum
were collected prior to dosing, on days 7, 14, 18 and 21 and at time of
death, and exposure was determined using high performance ELISA.
Results: In total, 13 groups of 3 dogs each underwent surgery and,
after 1 month of disease progression, were randomly assigned to a
treatment, including an untreated control group. The dosing procedure
was well tolerated by all dogs. Dogs treated once with 30 mg AS902330
had improved gross scores for the medial tibial plateau (40%) and tibial
and femoral cartilage degeneration (40%), compared with controls. De-
creased combined gross scores were evident for most AS902330-treated
knees compared with controls. Microscopic evaluation revealed deﬁnite
anabolic effects, including increased cloning, cellularity and proteoglycan
staining in lesion areas in dogs treated with 30mg AS902330; these
changes were most identiﬁable on femoral condyles. Convincing anabolic
effects were observed in a dose-dependent manner at the lower tiw
and once-weekly doses. AS902330-induced effects were found in the
upper third to half of the cartilage or matrix adjacent to deeper clefts.
Dogs from all treatment groups showed a reduction in histopathological
tibial cartilage degeneration; the greatest decrease was in dogs treated
once weekly with 30mg AS902330. Synovitis was minimal or mild with no
difference between groups, and subchondral bone sclerosis was highly
variable. No treatment-related changes in clinical chemistry parameters
or haematology were noted. Additionally, no systemic effects were seen
at any dose, as assessed using cartilage thickness in the ear, sternum
and trachea. Systemic exposure after intra-articular administration of
AS902330 was below the lower limit of quantiﬁcation (50 pg/mL).
Conclusions: Intra-articular treatment with the anabolic agent AS902330
30mg/wk resulted in deﬁnite anabolic effects in all treated knees, with
no apparent systemic effects. AS902330 demonstrated efﬁcacy in the
improvement of gross pathology and histopathology scoring in a dose-
dependent manner in this pilot study involving a dog meniscectomy
model, supporting earlier ﬁndings in rats.
74 PHARMACOKINETIC ANALYSIS OF RECOMBINANT LUBRICIN
FOLLOWING INTRA-ARTICULAR SUPPLEMENTATION IN RAT
KNEE JOINTS
M.A. Rivera-Bermudez, D. Daugusta, Q. Wang, J. Li, A. Root,
R. Zollner, C. Resmini, C. Flannery, S.S. Glasson, E.A. Morris. Wyeth
Research, Cambridge, MA, USA
Purpose: We have developed a novel recombinant lubricin construct,
LUB:1, which is chondroprotective and prevents cartilage degeneration
in a rat meniscal tear model of osteoarthritis (OA). LUB:1 contains a
truncated mucin-like domain, and maintains essential properties of car-
tilage binding and lubrication, and prevention of cell adhesion. The goal
of this study was to determine the residence time and tissue localization
of radiolabelled LUB:1 following intra-articular administration in the knee
joints of rats.
Methods:Male Lewis rats were dosed with a single bilateral intra-articular
injection of 125I-labeled LUB:1 (1mCi; 20mg/knee) and the knee joints
were collected at different time points (0.2 hours-672 hours). The retention
of 125I-labeled LUB:1 and tissue localization in the knee were assessed
by gamma counting of whole knees and dissected joint tissues (cartilage,
synovium, meniscus) and autoradiography.
Results: A fast decline in 125I-LUB:1 concentrations in the whole knee
occurred during the ﬁrst 24 hours (initial phase), indicating rapid clearance
from the synovial ﬂuid (i.e. via lymphatic transport) as has been described
for other macromolecules such as hyaluronan and albumin. This was
followed by a slow decline in 125I-LUB:1 levels, up to 672 hours. The
average elimination half-life of intra-articularly injected LUB:1, determined
from a one-compartmental ﬁt, was 152 hours. 125I-LUB:1 remained
detectable in the knee joint (particularly on the articular cartilage and
synovium) even at 672 hours (28 days) after a single injection. 125I-LUB:1
localized onto the surfaces of articular cartilage (tibial plateau, femoral
condyle and meniscus), synovium and cruciate ligament as determined
by autoradiography.
Conclusions: These data indicate that intra-articularly delivered LUB:1
localizes to the surfaces of joint tissues, including articular cartilage,
suggesting that at least part of its mechanism of action for slowing OA
progression may be by providing a protective coating at cartilage sur-
faces. The extended tissue residence time of LUB:1 in the joint supports
strategies for potential application of recombinant lubricin molecules as
therapeutics in the clinic.
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TESTING OF THERAPEUTICS FOR POSTOMENOPAUSAL
ARTHRITIS
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Medtronic, Minneapolis, MN, USA
Purpose: In the ﬁeld of osteoarthritis (OA) research, there is no consen-
sus as to which animal model best represents human OA, particularly
because the disease process isn’t completely understood. The primary
objective of this study was to validate the robustness of the ovarectomy
(OVX) model as a model of OA. The study was also used to identify
relevant therapeutic endpoints and to determine if rat strain plays a role
in the severity of the disease state. Endpoints reported in the literature
for this model were used as positive controls to monitor the progression
of the model. Several additional novel endpoints were also tested.
Methods: At 20 weeks (5 months) of age, 6 Sprague Dawley (SD) and
7 Long Evans (LE) female rats underwent OVX and 2 of each strain
underwent sham OVX. Weekly urine samples were collected beginning at
6 weeks. These were analyzed using the RatLapsTM ELISA (CTX-I) and
Urine Pre-Clinical CartiLaps® ELISA (CTX-II) kits (Nordic Biosciences)
to identify bone and cartilage breakdown products. The animals were
euthanized at 10 and 14 weeks post OVX (3 OVX/1 sham per breed per
time-point.) The right elbow and right stiﬂe (knee) joint were harvested
and snap frozen for RNA harvest and qPCR analysis. The genes analyzed
by qPCR included extra cellular matrix molecules, cytokines, cytokine
receptors, metalloproteases and growth factors. The left elbow and a
control knee were harvested and placed into ﬁxative for scanning electron
microscopy (SEM) analysis. The left knee of each animal was ﬁxed for
mCT imaging of bone architecture and later histological processing (H&E,
safranin-O and toluidine blue). A specially designed holder was used to
maintain ﬂexion and to allow for consistent imaging of the joint space
with a faxitron. Measurements of the joint space were then made using
Image-Pro® Software.
Results: The OVX model has been described in the literature as a
model for both osteoporosis and osteoarthritis. Previous studies have
reported signiﬁcant changes in the breakdown of bone and cartilage
in the ovariectomized animal. In keeping with these ﬁndings, the OVX
groups of both strains displayed initially elevated urinary CTX-I and II.
The qPCR gene analysis of the knees showed that certain extra-cellular
matrix proteins and proteases also tended to be higher at week 10 than
at week 14. In spite of these ﬁndings, SEM analysis did not show any
articulating surface damage on the condyles of the distal femur, humerus
or ulna articulating surfaces. No signiﬁcant differences were seen in
the joint narrowing index at weeks 10 and 14 between test and control
animals. There were, however, signiﬁcant bone changes following OVX,
as measured by mCT in both strains of rats. The LE rats displayed more
signiﬁcant bone changes than the SD. The pathology results showed that
no animals developed the classical morphological changes associated
with OA. At 10 and 14 weeks post-OVX, there was complete tidemark
integrity, normal cell organization and intact cartilage structure in the
knees of all animals.
Conclusions: More signiﬁcant osteoarthritic changes were expected
based upon previous ﬁndings. It may be that older animals or later time
points would demonstrate greater degeneration of bone and cartilage or
that exercise could be used to hasten these changes. Ovariectomy may
be better utilized as a background for other models.
